Annual Meeting Final Program. September 3 rd to 5 th, Grand Coral Beach Spa & Resort Cancun, Mexico

Transcripción

1 Annual Meeting 2015 Final Program September 3 rd to 5 th, 2015 Grand Coral Beach Spa & Resort Cancun, Mexico

2 Organization& Scientific Program Committee Society of Surgical Oncology Jeffrey Drebin, MD, PhD, FACS President of the Society Of Surgical Oncology Chairman, Department of Surgery John Rhea Barton Professor of Surgery University of Pennsylvania Health System Daniel G. Coit, MD, FACS President Elect SSO Professor of Surgery Memorial Sloan Kettering Cancer center, New York, USA. Suzanne Klimberg, MD Past- President SSO Director of the UAMS Breast Cancer Program University of Arkansas for Medical Sciences (UAMS), Arkansas, USA Charles M. Balch, MD Past-President SSO Professor of Surgery, University of Texas Southwestern Medical Center, Editor in Chief Annals Surgical of Oncology Dallas, Texa. USA Peter Beistch MD, FACS Department of Breast Surgical Oncology Medical City Dallas Hospital Past-President American Society of Breast Surgeons Mitchell Posner, MD Professor of Surgery Section of General Surgery, Surgical Oncology, Medical Director, Clinical Cancer Programs University of Chicago, Chicago, ILL, USA Eleftherios (Terry) P. Mamounas, MD, MPH, FACS Professor of Surgery UF Health Cancer Center Orlando, FL, USA.

3 Organization& Scientific Program Committee Instituto Nacional de Cancerologia Abelardo Meneses García, MD Director General Eduardo E. Cervera Ceballos, MD Director De Docencia Ángel Herrera Gómez, MD Director General Adjunto Médico Gonzalo Montalvo Esquivel, MD Sub-Director de Cirugia Juan Enrique Bargallo Rocha, MD Profesor Titular Del Curso Jefe de Departamento Tumores Mamarios Instituto Nacional de Cancerologia Hector Martínez Said, MD Profesor Titular Del Curso Coordinador Clínica de Melanoma Instituto Nacional de Cancerologia Sylvia Verónica Villavicencio Valencia, MD Profesor Titular Del Curso Subdirectora de Educacion Medica Instituto Nacional de Cancerologia

4 FACULTY International Professor Jeffrey Drebin, MD, PhD, FACS President of the Society of Surgical Oncology University of Pennsylvania Health System Daniel G. Coit, MD, FACS President Elect SSO Memorial Sloan Kettering, NY, USA. Suzanne Klimberg, MD University of Arkansas for Medical Sciences Charles Balch, MD University of Texas Southwestern Medical Center Peter Beitsch, MD, FACS University of Texas Southwestern Medical Center Mitchell Posner, MD University of Chicago, Chicago, ILL, USA Eleftherios (Terry) P. Mamounas MD, MPH, FACS UF Health Cancer Center Orlando, FL, USA. Latinamerican Professors Carlomagno Castillero Pinilla, MD Panama, Panama Eduardo Gharzouzi Bassila, MD Guatemala, Guatemala Herbert Castillo Oliva, MD Guatemala, Guatemala Jorge Rodríguez Bendaña, MD Tegucigalpa, Honduras Xavier Kon Jara, MD Portoviejo, Ecuador National Professors Aaron Gonzalez Enciso, MD Alberto Tavares de la Paz, MD Hospital Regional de Alta Especialidad del Bajío Alejandro E. Padilla Rosciano, MD Amancio Gatica Pérez MD Puebla, Puebla Ángel Herrera Gómez, MD Antonio Gómez Pedraza, MD Antonio Maffuz Aziz, MD Centro Médico ABC Arturo Lavín Lozano, MD Tepic, Nayarit Carlos G. Parra Torres MD Carlos Robles Vidal, MD Cynthia M. Villarreal Garza, MD Christian H Flores Balcázar, MD Instituto Nacional de Cancerologia Daniel Alcalá Pérez, MD Sociedad Mexicana de Cirugía Dermatológica y Oncológica Dorian Yarih García Ortega, MD Instituto Nacional de Cancerologia Edgardo Jiménez Fuentes, MD Erika B. Ruiz García, MD Francisco J. Ochoa Carrillo, MD Germán Calderillo Ruiz, MD Gonzalo Montalvo Esquivel, MD Gregorio Quintero Beuló, MD Hospital General de México

5 Guillermo Flores Ayala, MD Instituto Jalisciense de Cancerología, Jalisco Héctor Gurrola Machuca, M.D. Centro Médico Nacional, "20 de Noviembre" ISSSTE Héctor Martínez Said, MD Heriberto Medina Franco, MD Instituto Nacional de Ciencias Médicas y Nutrición Dr. Salvador Zubirán Horacio Noé López Basave, MD Itzel Vela Sarmiento, MD Javier Melchor Rúan, MD Jaime Corona Rivera, MD José Francisco Corona Cruz, MD José Luis Barrera Franco, MD Centro Oncológico Estatal, ISSEMYM Toluca Juan Enrique Bargalló Rocha, MD Juan Manuel Medina Castro, MD Centro Oncológico Estatal, ISSEMYM Toluca Juan Manuel Ruiz Molina, MD Judith Domínguez Cherit, MD Instituto Nacional de Ciencias Médicas y Nutrición Dr. Salvador Zubirán Karla Susana Martín Téllez, MD Kuauhyama Luna Ortiz, MD Luis Manuel Domínguez Parra, MD Hospital Regional de Alta Especialidad de la Península María Teresa Ramírez Ugalde, MD María Fernanda Hurtado Díaz, MD Skin Project Center María Teresa de J. Vega González, MD Mariela Montoya Montes de Oca, MD Xalapa, Veracruz Mario Cuellar Hübbe, MD Martín Granados García, MD Miguel Ángel Álvarez Avitia, MD Mónika Blake Cerda, MD Nereida Esparza Arias, MD Óscar G. Arrieta Rodríguez, MD Pabel Miranda Aguirre, MD Centro Médico Nacional 20 de Noviembre ISSSTE Paula A. Cabrera Galeana, MD Pedro Luna Pérez, MD Hospital de Oncología CMN Siglo XXI, IMSS Rafael Medrano Guzmán, MD Hospital de Oncología CMN Siglo XXI, IMSS Rafael Padilla Longoria, MD Centro Médico ABC Rafael Vázquez Córdova, MD Rafael Vázquez Romo, MD Roberto Antonio Rodríguez García, MD Rolando R. García Matus, MD Hospital Regional de Alta Especialidad de Oaxaca Rubén Cortés González, MD Instituto Nacional de Ciencias Médicas y Nutrición Dr. Salvador Zubirán Salvador Camacho Gutiérrez, MD Guadalajara, Jalisco Saúl E. Rodríguez Ramírez, MD Hospital de Oncología CMN Siglo XXI, IMSS Seir Alfonso Cortés Cárdenas, MD Centro Médico Nacional, "20 de Noviembre" ISSSTE Sinuhé Barroso Bravo, MD Hospital de Oncología CMN Siglo XXI, IMSS Sylvia Verónica Villavicencio Valencia, MD Vincenzo Aiello Crocifoglio, MD

6 Thursday September 3 rd CORAL KINGDOM, 2nd Floor 7:00-8:30 hrs M e e t t h e P r o f e s s o r B r e a k f a s t Breast Cancer: Personalized care for early stage in breast cancer Eleftherios (Terry) P. Mamounas, MD, MPH, FACS Professor of Surgery UF Health Cancer Center Orlando, FL, USA. MODERATOR: PANEL: Rafael Vázquez Romo, MD Suzanne Klimberg, MD University of Arkansas for Medical Sciences (UAMS) Amancio Gatica Pérez, MD Puebla, Puebla María Teresa Ramírez Ugalde, MD

7 CORAL KINGDOM, 2nd Floor 9:00-10:30 hrs I n a u g u r a l C o n f e r e n c e MODERATOR: Ángel Herrera Gómez, MD The evolution of targeted therapeutics in cancer Jeffrey Drebin, MD, PhD, FACS President of the Society of Surgical Oncology Chairman, Department of Surgery John Rhea Barton Professor of Surgery University of Pennsylvania Health System Jeffrey Drebin, MD, PhD, FACS Discussion 10:00-10:30 PANEL: Charles Balch, MD University of Texas Southwestern Medical Center, Dallas, Texas Gonzalo Montalvo Esquivel, MD Francisco J. Ochoa Carrillo, MD Consejo Mexicano de Oncología Gregorio Quintero Beulo, MD Sociedad Mexicana de Oncología, México

8 CORAL KINGDOM, 2nd floor 10:30-11:00 hrs B e s t o f S S O P r e s e n t a t i o n s Breast Cancer Suzanne Klimberg, MD University of Arkansas for Medical Sciences (UAMS) MODERATORS: Heriberto Medina Franco, MD Instituto Nacional de Ciencias Médicas y Nutrición Dr. Salvador Zubirán Nereida Esparza Arias, MD Long-term Incidence of Lymphedema after Sentinel Lymph Node Dissection for Early Stage Breast Cancer: ACOSOG Z0010 (Alliance) M. Teshome*, J.N. Cormier, K.K. Hunt, The University of Texas M.D. Anderson Cancer Center, Houston, TX; K.V. Ballman, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; L.M. McCall, Alliance Statistics and Data Center, Duke University, Durham, NC; A.E. Giuliano, Samuel Oschin Comprehensive Cancer Institute, Cedar-Sinai Medical Center, Los Angeles, CA. Introduction: Sentinel lymph node (SLN) dissection has an established role as minimally invasive axillary staging with decreased morbidity in early breast cancer. The American College of Surgeons Oncology Group (ACOSOG) Z0010 trial, a prospective multicenter study to evaluate the prognostic significance of micrometastasis in SLNs of women with early stage breast cancer, previously reported a 7% incidence of lymphedema at 6 months. This study examines the long-term incidence of lymphedema in this cohort. Methods: Eligible patients for ACOSOG Z0010 included women with clinical T1-2 N0 M0 breast cancer. In this trial 5,210 women underwent SLN dissection; of those, 885 had completion axillary lymph node dissection (ALND) and were included for comparison. Post-operative symptoms assessment and examination were completed at 30 days, 6 months, and annually for 5 years. Lymphedema was evaluated subjectively as ipsilateral arm swelling and objectively as an increase of 2 cm from the pre-operative arm measurement. A multivariate Cox regression analysis was conducted to examine associations between clinical factors and lymphedema. Results: The cumulative incidence of lymphedema after SLN dissection was 3.7% at 1 year, 8.9% at 3 years and 11.9% at 5 years by subjective assessment (n=3,993) and 10.5% at 1 year, 17.4% at 3 years and 24.1% at 5 years by objective arm measurements (n= 3,918). Following ALND, the incidence of lymphedema was 14.0% at 1 year, 32.9% at 3 years and 41.0% at 5 years by subjective assessment (n=865) and 17.0% at 1 year, 30.6% at 3 years and 40.3% at 5 years by objective arm measurement (n= 853). On multivariate analysis, significant predictors of objective lymphedema included increasing age (OR=1.01, [95% CI: ], p<0.0001), BMI 30 kg/m2 (OR=1.81 [ ], p<0.0001) and ALND (OR=1.74 [ ], p<0.0001). After axillary surgery, decreased range of motion and paresthesias occurred more often than lymphedema. Conclusions: Lymphedema after SLN dissection in women with early stage clinically node negative breast cancer occurs more frequently than clinically suspected and with increasing incidence over time

9 CORAL KINGDOM, 2nd Floor 11:00-11:30 hrs B e s t o f S S O P r e s e n t a t i o n s Melanoma/ Soft Tissue Sarcomas Daniel G. Coit, MD, FACS Memorial Sloan Kettering Cancer Center MODERATORS: Mario Cuéllar Hübbe, MD Karla Susana Martín Téllez, MD Australian National Multi-Center Study of Isolated Limb Infusion Chemotherapy for Extremity Melanoma J.F. Thompson, Melanoma Institute Australia, North Sydney, New South Wales, Australia; H.M. Kroon*, B.J. Coventry, M.H. Giles, Royal Adelaide Hospital, Adelaide, South Australia, Australia; M. Henderson, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia; B. Smithers, Princess Alexandra Hospital, Brisbane, Queensland, Australia; J. Serpell, The Alfred Hospital, Melbourne, Victoria, Australia Introduction: Isolated limb infusion (ILI) is a minimally invasive alternative to isolated limb perfusion (ILP) for delivering high dose regional chemotherapy to an extremity. ILI is now progressively performed in many tertiary referral centers worldwide to treat patients with locally advanced limb melanoma. We investigated the results of ILI in a national Australian multicenter study. Methods: ILIs in 316 patients in five Australian institutions ( ) were collectively analyzed. All 5 institutions used the Melanoma Institute Australia ILI protocol. Melphalan and actinomycin D was circulated in the isolated limb for minutes. Cancer response was determined using the WHO criteria and limb toxicity was assessed using the Wieberdink Scale. Results: The median patient age was 74 years (range ) and 59% were female. Overall response rate to ILI was 75%, consisting of a complete response of 33% and a partial response of 42%. Stable disease was seen in 18% and progressive disease in 7%. Wieberdink toxicity grade III or higher was seen in 30% of the cases. No toxicity-related amputations occurred. Median followup was 22 months and median survival was 48 months. In patients with a CR, median survival was 80 months (p = 0.014). In the univariate analysis a younger age, lower-limb procedures, low Breslow thickness of the primary melanoma and intra-operatively higher achieved intramuscular temperatures were associated with a favorable response. On multivariate analysis Breslow thickness and lower-limb ILI remained significant predictors for response. Conclusion: This Australian national ILI multi-center study is the largest to date. Toxicity and response rates as well as survival are comparable to other studies reporting results following both ILI and conventional ILP. ILI can widely be implemented and safely applied across tertiary referral centers for successful management of advanced extremity melanoma

10 CORAL KINGDOM, 2nd floor 11:30-12:00 hrs B e s t o f S S O P r e s e n t a t i o n s Gastrointestinal Cancer Mitchell Posner, MD University of Chicago, Chicago, ILL, USA MODERATORS: Aarón González Enciso, MD Roberto Antonio Rodríguez García, MD NSABP FC-6: Phase II Study to Determine Surgical Conversion Rate in Patients (pts) Receiving Neoadjuvant (NA) mfolfox7 Plus Dose-escalating Cetuximab (C) for Unresectable K-RAS Wild-type (WT) Colorectal Cancer with Metastases (mcrc) Confined to the Liver L.D. Wagman*, National Surgical Adjuvant Breast and Bowel Project (NSABP), and St Joseph Hospital, Orange, CA; D.A. Geller, NSABP, and the University of Pittsburgh Medical Center, UPMC Liver Cancer Center, Pittsburgh, PA; S.A. Jacobs, NSABP, and the University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA; N.J. Petrelli, NSABP, and Christiana Care Health Service/Helen F. Graham Cancer Center, Newark, DE; C.J. Allegra, NSABP, and the University of Florida, Gainesville, FL; M. Buyse, International Drug Development Institute, Brussels, Belgium; N. Wolmark, NSABP, and Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA; M.J. O'Connell, NSABP, Pittsburgh, PA Based on pre-defined endpoints, the purpose of the FC-6 study is to determine the surgical conversion rate for liver-only metastatic CRC in KRAS WT pts treated with neoadjuvant mfolfox7 plus doseescalating cetuximab. Eligibility: Untreated KRAS WT mcrc confined to liver. Initial unresectability was determined by an experienced surgical oncologist based on liver metastases that cannot be resected/ablated to R0 with >40% and/or 3 uninvolved segments of liver remaining. Prior adjuvant therapy was allowed if chemo-free interval >6 months. Treatment: Oxaliplatin 85 mg/m2 iv, leucovorin 400 mg/m2 iv, 5-FU 3000 mg/m2 iv continuous infusion over 46 hours, C 500 mg/m2 iv (C escalated by 100 mg/m2 q 2 wks to max dose of 800 mg/m2) on d 1, 15, 29, and 43 of each 8-wk cycle. Prophylactic doxycycline 100 mg po bid and application of topical emollient bid was required. A total of 3 cycles were planned, including pre-and post-operative cycles. Pts were evaluated after each cycle for resectability. Results: Of 20 pts enrolled, 2 had prior adjuvant therapy. 17 of 20 had at least one dose of escalated C (median dose intensity 632 mg/m2/2-wk). 18 of 20 underwent attempt at surgical resection; all pts were evaluable for toxicity. Grade 4 adverse events included neutropenia (1) and thrombocytopenia (1), sepsis and pulmonary embolism (1). Grade 3 rash occurred in 4 pts. Six, 8, and 4 pts were deemed resectable after cycles 1, 2, and 3 respectively. Four were found to be unresectable at surgery. Time from end of chemo to OR: d (median 35d). Best response to neoadjuvant chemotherapy: CR 1, PR 15, SD 3, and PROG of 20 had surgical R0 for conversion rate of 70%. Surgical-specific G3/4 morbidity occurred in 2 pts. Conclusion: mfolfox plus escalated C is highly active and resulted in excellent conversion rate with manageable toxicity. It is too early to project longterm survival. In selected KRAS WT pts with mcrc, mfolfox7 plus C therapy is worthy of investigation as a first-line option

11 B R E A K 12:00 12:30 CORAL KINGDOM, 2nd floor 12:30-13:15 hrs Interactive multidisciplinary case presentation Colorectal cancer CLINICAL CASE PRESENTER: Itzel Vela Sarmiento, MD PARTICIPANTS: Horacio Noé López Basave, MD Juan Manuel Ruiz Molina, MD Erika B. Ruiz García, MD Pedro Luna Pérez, MD Centro Médico Nacional Siglo XXI Mariela Montoya Montes de Oca, MD Xalapa, Veracruz Arturo Lavín Lozano, MD Tepic, Nayarit Guillermo Flores Ayala, MD Guadalajara, Jalisco Jorge Rodríguez Bendaña, MD Tegucigalpa, Honduras

12 CORAL KINGDOM, 2nd floor 13:15-14:00 hrs Interactive multidisciplinary case presentation Melanoma Sarcomas CLINICAL CASE PRESENTER: Dorian Yarih García Ortega, MD PARTICIPANTS: Daniel G. Coit, MD, FACS Memorial Sloan Kettering, NY, USA. Charles Balch, MD University of Texas Southwestern Medical Center Sylvia Verónica Villavicencio Valencia, MD Miguel Ángel Álvarez Avitia, MD Alberto Tavares de la Paz, MD Hospital Regional de Alta Especialidad del Bajío Pabel Miranda Aguirre, MD Centro Médico Nacional 20 de Noviembre ISSSTE Xavier Kon Jara, MD Portoviejo, Ecuador

13 CORAL KINGDOM, 2nd floor 14:00-14:45 hrs Interactive multidisciplinary case presentation Thoracic oncology CLINICAL CASE PRESENTER: José Francisco Corona Cruz, MD PARTICIPANTS: Edgardo Jiménez Fuentes, MD Rafael Vázquez Córdova, MD Carlos G. Parra Torres, MD Óscar Gerardo Arrieta Rodríguez, MD Mónika Blake Cerda, MD Rafael Padilla Longoria, MD Centro Médico ABC Luis Manuel Domínguez Parra, MD Hospital Regional de Alta Especialidad de la Península de Yucatán Herbert Castillo Oliva, MD Guatemala, Guatemala B R E A K 14:45 15:30

14 CORAL KINGDOM, 2nd Floor 15:30-17:30 hrs Great Debates in Surgical Oncology Sentinel lymph node biopsy should be performed on all patients with cutaneous melanoma 1 mm thick 15:30 16:30 MODERATOR: Héctor Martínez Said, MD. 20 Pro: Daniel Coit, MD Memorial Sloan Kettering Cancer Center, NY 20 Con: Charles Balch, MD University of Texas Southwestern Medical Center 20 Discussion Minimally invasive surgery versus open for upper gastrointestinal cancer 16:30 17:30 MODERATOR Horacio Noé López Basave, MD 20 Pro Mitchell Posner, MD University of Chicago, Chicago, ILL, USA 20 Con Jeffrey Drebin, MD, PhD, FACS University of Pennsylvania Health System 20 Discussion

15 Grand Coral III, 4th Floor 18:00-21:00 hrs G r e a t I n a u g u r a l C o n g r e s s C o n f e r e n c e I n t e r n a t i o n a l A c a d e m i c O n c o l o g y M e e t i n g The Best of Society of Surgical Oncology (SSO) The Best of American Society Clinical Oncology (ASCO) Hemato-Oncology Conference (HOC) Selected Topics in Radiotherapy Palliative Care for Oncology Selected Topics in Gynecology Oncology Anesthesia Management and Cancer Support Reception Cocktail & Expo Inauguration Welcome Reception

16 Friday September 4 th CORAL KINGDOM, 2nd Floor 7:00-8:30 hrs M e e t t h e P r o f e s s o r B r e a k f a s t Melanoma Melanoma therapy: What have we learned lately? Daniel Coit, MD, FACS. Thomas D. Jones Professor of Surgery Chief, Section of General Surgery Chief, Surgical Oncology Medical Director, Clinical Cancer Programs University of Chicago, Chicago, ILL, USA MODERATOR: PANEL: Mario Cuéllar Hübbe, MD Salvador Camacho Gutiérrez, MD Guadalajara, Jalisco Eduardo Gharzouzi Bassila, MD Guatemala, Guatemala 9:00 15:00

17 CORAL KINGDOM, 2nd Floor 14:30-15:15 hrs Interactive Multidisciplinary Case Presentation Advanced skin cancer CLINICAL CASE PRESENTER: María Teresa de J. Vega González, MD PARTICIPANTS: Martín Granados García, MD Kuauhyama Luna Ortíz, MD Antonio Gómez Pedraza, MD Héctor Gurrola Machuca, MD Centro Médico Nacional 20 de Noviembre ISSSTE Daniel Alcalá Pérez, MD Sociedad Mexicana de Cirugía Dermatológica y Oncológica María Fernanda Hurtado Díaz, MD Skin Project Center Judith Domínguez Cherit, MD Instituto Nacional de la Nutrición Dr. Salvador Zubirán M.D. Instituto

18 CORAL KINGDOM, 2nd Floor 15:15-16:00 hrs Interactive Multidisciplinary Case Presentation CLINICAL CASE PRESENTER: Upper gastrointestinal cancer Juan Manuel Ruiz Molina, MD PARTICIPANTS: Mitchell Posner, MD University of Chicago, Chicago, ILL, USA Vincenzo Aiello Crocifoglio, MD Alejandro E. Padilla Rosciano, MD Germán Calderillo Ruiz, MD Seir Alfonso Cortés Cárdenas, MD Centro Médico Nacional 20 de Noviembre ISSSTE Juan Manuel Medina Castro, MD Centro Oncológico Estatal, ISSEMYM Toluca Rolando R. García Matus, MD Hospital Regional de Alta Especialidad de Oaxaca Rubén Cortés González, MD Instituto Nacional de la Nutrición Dr. Salvador Zubirán

19 CORAL KINGDOM, 2nd floor 16:00-16:45 hrs Interactive Multidisciplinary Case Presentation Breast Cancer CLINICAL CASE PRESENTER: Jaime Corona Rivera, MD PARTICIPANTS: Suzanne Klimberg, MD University of Arkansas for Medical Sciences Terry Mamounas, MD UF Health Cancer Center Orlando, FL, USA. Peter Beitsch, MD, FACS Medical City Dallas Hospital Carlos Robles Vidal, MD Paula A. Cabrera Galeana, MD Christian H. Flores Balcázar, MD Cynthia M. Villarreal Garza, MD Sinuhé Barroso Bravo, MD Centro Médico Nacional Siglo XXI Antonio Maffuz Aziz, MD Centro Médico ABC

20 CORAL KINGDOM, 2nd floor 17:00-18:30 hrs The Best of SSO Closing Conference GREAT DEBATES IN BREAST CANCER MODERATORS: Peter Beitsch, MD, FACS Medical City Dallas Hospital Juan Enrique Bargalló Rocha, MD, México Topic: Management of DCIS: Are we overtreating? 10 Yes Charles Balch, MD University of Texas Southwestern Medical Center 10 No Terry Mamounas, MD UF Health Cancer Center Orlando, FL, USA. 10 Discussion Topic: Margin width in breast conserving surgery: No ink on tumor? 10 Yes Terry Mamounas, MD UF Health Cancer Center Orlando, FL, USA. 10 No

21 Suzanne Klimberg, MD University of Arkansas for Medical Sciences 10 Discussion Topic: Is sentinel lymph node biopsy accurate for staging after chemotheraphy in patients with initial node positive disease? 10 Yes Charles Balch, MD University of Texas Southwestern Medical Center 10 No Suzanne Klimberg MD University of Arkansas for Medical Sciences 10 Discussion 19:30 21:00 hrs Place: Socialize with collegues in your disease track in a casual Happy Hour Saturday

22 September 5 th CORAL KINGDOM, 2nd Floor 7:00-8:30 hrs M e e t t h e P r o f e s s o r B r e a k f a s t Gastrointestinal cancer Multimodality therapy: Which approach is best for borderline resectable pancreatic cancer? Mitchell Posner, MD Thomas D. Jones Professor of Surgery Chief, Section of General Surgery Chief, Surgical Oncology Medical Director, Clinical Cancer Programs University of Chicago, Chicago, ILL, USA MODERATOR: PANEL: Javier Melchor Ruan, MD Saúl E. Rodríguez Ramírez, MD Centro Médico Nacional Siglo XXI, IMSS Carlomagno Castillero Pinilla, MD Panamá, Panamá

23 9:00 15:00 Meeting Grupo de Investigación en Sarcomas de México 4ª. Reunion del Consenso Nacional 09:00-10:00 hrs MODERATOR: PANEL: Hector Martínez Said, MD Mario Cuellar Hübbe, MD José Francisco Corona Cruz, MD Sylvia Verónica Villavicencio Valencia, MD José Luis Barrera Franco, MD Centro Oncológico Estatal, ISSEMYM, Toluca Rafael Padilla Longoria, MD Centro Médico ABC Rafael Medrano Guzmán, MD Centro Médico Nacional Siglo XXI, IMSS Pabel Miranda Aguirre, MD Centro Médico Nacional 20 de Noviembre ISSSTE Alberto Tavares de la Paz, MD Hospital Regional Alta Especialidad del Bajío, Leon, Guanajuato

24

25 Thursday Friday SATURDAY 7:00-7:30 7:00-7:30 7:30-8:00 7:30-8:00 8:00-8:30 8:00-8:30 8:30 9:00 8:30 9:00 9:00 9:30 REUNION GRUPO DE INVESTIGACION 9:00 9:30 DE SARCOMAS EN MEXICO GISM 9:30 10:00 9:30 10:00 10:00 10:30 10:00 10:30 10:30 11:00 10:30 11:00 11:00 11:30 11:00 11:30 11:30 12:00 11:30 12:00 12:00 12:30 12:00 12:30 12:30 13:00 12:30 13:00 13:00 13:30 13:30 14:00 14:00 14:30 14:30 15:00 15:00 15:30 15:30 16:00 Arrivals MEET THE PROFESSOR BREAKFAST Terry Mamounas / Suzanne Klimberg INAUGURAL CONFERENCE Jeffrey Drebin (09:00-10:30) BEST OF SSO PRESENTATIONS (10:30-12:00) BREAK (12:00 a 12:30) Interactive Multidisciplinary Case Presentation (Colorectal Cancer) (12:30-13:15) Interactive Multidisciplinary Case Presentation (Melanoma - Sarcomas) (13:15-14:00) Interactive Multidisciplinary Case Presentation (Thoracic Oncology) (14:00-14:45) BREAK (14:45-15:30) Great Debates in Surgical Oncology (Pro vs Con) (15:30-17:30) MEET THE PROFESSOR BREAKFAST Daniel Coit BEST OF ASCO Interactive Multidisciplinary Case Presentation (Advanced Skin Cancer) (14:30-15:15)) Interactive Multidisciplinary Case Presentation (Upper GI Cancer) (15:15-16:00) Interactive Multidisciplinary Case Presentation (Breast Cancer) (16:00-16:45) MEET THE PROFESSOR BREAKFAST Mitchell Posner BEST OF ASCO 16:00 16:30 16:00 16:30 16:30 17:00 16:30 17:00 13:00 13:30 13:30 14:00 14:00 14:30 14:30 15:00 15:00 15:30 15:30 16:00 17:00 17:30 17:00 17:30 17:30 18:00 17:30 18:00 18:00-18:30 18:00-18:30 GREAT INAUGURAL CONGRESS CONFERENCE INTERNATIONAL ACADEMIC ONCOLOGY MEETING CLOSING CONFERENCE GREAT DEBATES IN BREAST CANCER 18:30-19:00 18:30-19:00 19:00-19:30 19:00-19:30 Reception Cocktail & Expo Inauguration Happy Hour 19:30-20:00 19:30-20:00 Socialize with collegues in your disease track in a casual Happy Hour 20:00-21:00 20:00-21:00 21:00-22:00 21:00-24:00